Endocrine pancreas cancer and exocrine pancreas cancer are two types of pancreatic cancer. These cancerous cells become more malignant when they migrate to the other part of the body through blood. It is one of the least treatable forms of cancer around.
According to the WHO, cancer was the leading cause of the total number of deaths globally in 2015 and was responsible for 8.8 million deaths. Furthermore, pancreatic cancer was the twelfth most common type of cancer in the same year. The factors that cause pancreatic cancer are cigarettes, cigars, pipes and chewing tobacco. According to the study done by Cancer Research U.K, looking at the lifestyle factors found that out of three pancreatic cancer, one may be linked to smoking. Additionally, around seven out of ten cases of chronic pancreatitis are due to long-term heavy consumption of alcohol.
Pancreatic cancer is hard to catch, even if we are aware of the symptoms to search for. This leads to a late diagnosis and makes treatment more difficult. Many treatments for pancreatic cancer are available in the market such as chemotherapy, surgery, radiotherapy, and targeted therapy. Whereas the surgery is considered as a first treatment option for pancreatic cancer, just like any other cancer. Pancreatic cancer is one of the painful cancers, and the survivor gets relief only if they get treatment on early stage. Furthermore, these treatments prolong the lifespan of the patient if treated on time. Thus, the earlier it is detected, the better would be the prognosis.
Moreover, advancing technology in medical devices is adding fuel to the growth of the market. Furthermore, increasing prevalence of cancer drives the market growth. However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors which may hamper the market growth during the forecast period.
The global pancreatic cancer market is expected to grow at a CAGR of 8.1% during the forecast period 2017-2023.
Segmentations
The global pancreatic cancer market is segmented on the basis of types, treatment, and end user.
On the basis of the type, it is segmented into endocrine pancreas cancer, exocrine pancreas cancer, and others.
On the basis of the treatment, it is segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy, and others. Furthermore, the chemotherapy is segmented into antimetabolites, anthracyclines, taxanes, and alkylating agents. The targeted therapy is sub-segmented into tyrosine kinase inhibitors and monoclonal antibodies. And the hormone therapy is sub-segmented into estrogen-receptor modulators, aromatase inhibitors, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research institute, and others.
Key Players
Some of key the players in the market are Pharmacyte Biotech Inc. (U.S.), OncoGenex Pharmaceuticals Inc. (U.S.), Oncolytics Biotech (Canada), Diffusion Pharmaceuticals (U.S.), Polaris Pharmaceuticals, Inc. (U.S.), Sun BioPharma, Inc. (U.S.), Midatech Pharma PLC (U.K.), Eli Lilly and Company (U.S.), Celgene Corporation (U.S.), F. Hoffmann-La Roche AG (Switzerland), Amgen, Inc. (U.S.), Novartis International AG (U.S.), Clovis Oncology (U.S.), and others.
Request Customization
Get a Sample
Get a Sample
Request Customization